Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.
The circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3509137?pdf=render |
| _version_ | 1819161242794721280 |
|---|---|
| author | Jeanne Sibiude Jean Guibourdenche Marie-Danielle Dionne Camille Le Ray Olivia Anselem Raphaël Serreau François Goffinet Vassilis Tsatsaris |
| author_facet | Jeanne Sibiude Jean Guibourdenche Marie-Danielle Dionne Camille Le Ray Olivia Anselem Raphaël Serreau François Goffinet Vassilis Tsatsaris |
| author_sort | Jeanne Sibiude |
| collection | DOAJ |
| description | The circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or intrauterine growth restriction (IUGR).A double blind prospective study. We enrolled 96 women for suspected preeclampsia or IUGR, and measured plasma levels of PlGF (Triage®) at enrolment. We defined adverse outcome as severe preeclampsia, SGA neonate (<10(th) centile) or elective delivery for maternal or fetal complication. Severe adverse outcome was studied among patients included <34 weeks gestation (WG) and defined as eclampsia, HELLP syndrome, very SGA (<3(rd) centile) or elective delivery <34 WG. The mean logtransformed PlGF level was lower for women who experienced preeclampsia (2.9 vs 3.7, p = 0.02), and was markedly lower for patients who experienced adverse outcome (2.9 vs 4.3, p<0.001). The odds of presenting an adverse outcome were higher for the lowest tertile of PlGF compared to the higher (OR = 13 , 95% CI [3-50]). For severe adverse outcome, odds were respectively for the lowest and intermediate tertile as compared with the higher tertile : OR = 216, 95% CI [18-2571]; and OR = 17, 95% CI [3-94]. When included <34 WG, patients with a PlGF level <12 pg/ml experienced a severe adverse outcome in 96% of cases (24/25), and only 1 of 20 patients with a PlGF level >5(th) centile experienced a severe adverse outcome within 15 days (5%).Among women with suspected preeclampsia or IUGR, PlGF helps identify women who will experience an adverse outcome and those who will not within a time period of 15 days. |
| first_indexed | 2024-12-22T17:09:14Z |
| format | Article |
| id | doaj.art-b85c5fed31a14df99fab84d5746427dc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T17:09:14Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b85c5fed31a14df99fab84d5746427dc2022-12-21T18:19:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01711e5020810.1371/journal.pone.0050208Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.Jeanne SibiudeJean GuibourdencheMarie-Danielle DionneCamille Le RayOlivia AnselemRaphaël SerreauFrançois GoffinetVassilis TsatsarisThe circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or intrauterine growth restriction (IUGR).A double blind prospective study. We enrolled 96 women for suspected preeclampsia or IUGR, and measured plasma levels of PlGF (Triage®) at enrolment. We defined adverse outcome as severe preeclampsia, SGA neonate (<10(th) centile) or elective delivery for maternal or fetal complication. Severe adverse outcome was studied among patients included <34 weeks gestation (WG) and defined as eclampsia, HELLP syndrome, very SGA (<3(rd) centile) or elective delivery <34 WG. The mean logtransformed PlGF level was lower for women who experienced preeclampsia (2.9 vs 3.7, p = 0.02), and was markedly lower for patients who experienced adverse outcome (2.9 vs 4.3, p<0.001). The odds of presenting an adverse outcome were higher for the lowest tertile of PlGF compared to the higher (OR = 13 , 95% CI [3-50]). For severe adverse outcome, odds were respectively for the lowest and intermediate tertile as compared with the higher tertile : OR = 216, 95% CI [18-2571]; and OR = 17, 95% CI [3-94]. When included <34 WG, patients with a PlGF level <12 pg/ml experienced a severe adverse outcome in 96% of cases (24/25), and only 1 of 20 patients with a PlGF level >5(th) centile experienced a severe adverse outcome within 15 days (5%).Among women with suspected preeclampsia or IUGR, PlGF helps identify women who will experience an adverse outcome and those who will not within a time period of 15 days.http://europepmc.org/articles/PMC3509137?pdf=render |
| spellingShingle | Jeanne Sibiude Jean Guibourdenche Marie-Danielle Dionne Camille Le Ray Olivia Anselem Raphaël Serreau François Goffinet Vassilis Tsatsaris Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS ONE |
| title | Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. |
| title_full | Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. |
| title_fullStr | Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. |
| title_full_unstemmed | Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. |
| title_short | Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. |
| title_sort | placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction |
| url | http://europepmc.org/articles/PMC3509137?pdf=render |
| work_keys_str_mv | AT jeannesibiude placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT jeanguibourdenche placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT mariedanielledionne placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT camilleleray placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT oliviaanselem placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT raphaelserreau placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT francoisgoffinet placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction AT vassilistsatsaris placentalgrowthfactorforthepredictionofadverseoutcomesinpatientswithsuspectedpreeclampsiaorintrauterinegrowthrestriction |